Then, the authors found that PPBP, PROS1, and LCN2 were identified and validated to be related to PD and PPBP, LCN2 may potentially be biomarkers or therapeutic targets for PD in peripheral blood mononuclear cell. This evidence concerns the gene LCN2 and Parkinson disease.